Effects of the configuration of a multi-epitope chimeric malaria DNA vaccine on its antigenicity to mice

Chin Med J (Engl). 1999 Aug;112(8):686-90.

Abstract

Objective: Four B and Th cell epitopes were selected from conservative domain of Plasmodium falciparum antigens to construct two groups of chimeric malaria DNA vaccines with different configurations and their antigenicities were studied.

Methods: The partially synthesized oligonucleotide was annealed, PCR amplified and cloned into a mammalian cell expression vector. By using a pair of isocaudamers on the vector, different single copies of B epitopes were multiplied and were tenderly stringed into two groups of chimeric DNA vaccine with different configurations. BALB/c mice were immunized with these DNA plasmids by either intramuscular or intradermal injections.

Results: The antisera from the immunized mice tested by ELISA showed that only the configuration which had a single copy of universal T helper cell epitope, CS. T3, located at the C terminal of the multi-copy B cell epitopes induced a high antibody response. The T helper cell epitope at any other position of the peptide, or the double T helper cell epitopes configured with the B cell epitopes did not enhance antibody response, and some configurations even decreased the humoral response to a B cell epitope.

Conclusion: This study demonstrated that both combination and configuration of the epitope may affect the antigenicity of a chimeric multiple antigen.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Protozoan / blood
  • Antigens, Protozoan / immunology*
  • B-Lymphocytes / immunology
  • Epitopes
  • Female
  • Malaria / immunology*
  • Malaria Vaccines / immunology*
  • Mice
  • Plasmodium falciparum / immunology
  • Recombinant Fusion Proteins / immunology
  • T-Lymphocytes / immunology
  • Vaccines, DNA / immunology*

Substances

  • Antibodies, Protozoan
  • Antigens, Protozoan
  • Epitopes
  • Malaria Vaccines
  • Recombinant Fusion Proteins
  • Vaccines, DNA